Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06130579 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

StatusRecruiting
PhasePhase 2
Started2024-01-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 3, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-05-28
Study Status, Oversight v3
Primary completion date2024-12-31→2025-12-31
Completion date2025-06-30→2026-06-30
2024-03-19
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-12-01→confirmed 2024-01-01
Study sites0→1
2023-11-15
Study Status, Outcome Measures v1
Secondary endpoints5 entries, revised
The incidence of acute and chronic graft versus host disease (GvHD) The incidence of non-relaspserelapse mortality The probablityprobability of progression free survival The probablityprobability of overall survival (OS)
2023-11-08
Original filing
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Trial Details
NCT Number NCT06130579
Lead Sponsor Peking University People's Hospital
Conditions Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment 35 participants
Start Date 2024-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-03